Monoclonal antibody MA 33H1

Drug Profile

Monoclonal antibody MA 33H1

Latest Information Update: 29 Sep 2004

Price : $50

At a glance

  • Originator Sanofi-Synthelabo
  • Class Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Plasminogen activator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 29 Sep 2004 Discontinued - Preclinical for Thrombosis in France (unspecified route)
  • 27 Aug 1999 Sanofi and Synthélabo have now merged to form Sanofi-Synthélabo
  • 05 Nov 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top